PCM
LSTA icon

PenderFund Capital Management’s Lisata Therapeutics LSTA Stock Holding History

PenderFund Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238K Buy
+47,500
New +$196K 0.04% 128

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

PenderFund Capital Management's LSTA Position: Q1 2026 in Review

PenderFund Capital Management opened a new position in Lisata Therapeutics (LSTA) in Q1 2026: 47,500 shares worth $238K. The stake represents 0.04% of the portfolio and ranks #128 among its holdings.

34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • PenderFund Capital Management held 47,500 shares of Lisata Therapeutics worth $238K as of Q1 2026.
  • Lisata Therapeutics was a new PenderFund Capital Management position in Q1 2026.
  • Lisata Therapeutics made up 0.04% of PenderFund Capital Management's portfolio in Q1 2026, its #128 holding.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on PenderFund Capital Management's 13F filing for Q1 2026, filed 15 May 2026.